A complex ePrescribing-based Anti-Microbial Stewardship (ePAMS+) intervention for hospitals combining technological and behavioural components: protocol for a feasibility trial.

Bacteriology Decision support Health informatics Infectious diseases Microbiology

Journal

Pilot and feasibility studies
ISSN: 2055-5784
Titre abrégé: Pilot Feasibility Stud
Pays: England
ID NLM: 101676536

Informations de publication

Date de publication:
28 Jan 2023
Historique:
received: 23 05 2022
accepted: 16 12 2022
entrez: 28 1 2023
pubmed: 29 1 2023
medline: 29 1 2023
Statut: epublish

Résumé

Antimicrobial resistance is a leading global public health threat, with inappropriate use of antimicrobials in healthcare contributing to its development. Given this urgent need, we developed a complex ePrescribing-based Anti-Microbial Stewardship intervention (ePAMS+). ePAMS+ includes educational and organisational behavioural elements, plus guideline-based clinical decision support to aid optimal antimicrobial use in hospital inpatients. ePAMS+ particularly focuses on prompt initiation of antimicrobials, followed by early review once test results are available to facilitate informed decision-making on stopping or switching where appropriate. A mixed-methods feasibility trial of ePAMS+ will take place in two NHS acute hospital care organisations. Qualitative staff interviews and observation of practice will respectively gather staff views on the technical component of ePAMS+ and information on their use of ePAMS+ in routine work. Focus groups will elicit staff and patient views on ePAMS+; one-to-one interviews will discuss antimicrobial stewardship with staff and will record patient experiences of receiving antibiotics and their thoughts on inappropriate prescribing. Qualitative data will be analysed thematically. Fidelity Index development will enable enactment of ePAMS+ to be measured objectively in a subsequent trial assessing the effectiveness of ePAMS+. Quantitative data collection will determine the feasibility of extracting data and deriving key summaries of antimicrobial prescribing; we will quantify variability in the primary outcome, number of antibiotic defined daily doses, to inform the future larger-scale trial design. This trial is essential to determine the feasibility of implementing the ePAMS+ intervention and measuring relevant outcomes, prior to evaluating its clinical and cost-effectiveness in a full scale hybrid cluster-randomised stepped-wedge clinical trial. Findings will be shared with study sites and with qualitative research participants and will be published in peer-reviewed journals and presented at academic conferences. The qualitative and Fidelity Index research were approved by the Health and Research Authority and the North of Scotland Research Ethics Service (ref: 19/NS/0174). The feasibility trial and quantitative analysis (protocol v1.0, 15 December 2021) were approved by the London South East Research Ethics Committee (ref: 22/LO/0204) and registered with ISRCTN ( ISRCTN 13429325 ) on 24 March 2022.

Sections du résumé

BACKGROUND BACKGROUND
Antimicrobial resistance is a leading global public health threat, with inappropriate use of antimicrobials in healthcare contributing to its development. Given this urgent need, we developed a complex ePrescribing-based Anti-Microbial Stewardship intervention (ePAMS+).
METHODS METHODS
ePAMS+ includes educational and organisational behavioural elements, plus guideline-based clinical decision support to aid optimal antimicrobial use in hospital inpatients. ePAMS+ particularly focuses on prompt initiation of antimicrobials, followed by early review once test results are available to facilitate informed decision-making on stopping or switching where appropriate. A mixed-methods feasibility trial of ePAMS+ will take place in two NHS acute hospital care organisations. Qualitative staff interviews and observation of practice will respectively gather staff views on the technical component of ePAMS+ and information on their use of ePAMS+ in routine work. Focus groups will elicit staff and patient views on ePAMS+; one-to-one interviews will discuss antimicrobial stewardship with staff and will record patient experiences of receiving antibiotics and their thoughts on inappropriate prescribing. Qualitative data will be analysed thematically. Fidelity Index development will enable enactment of ePAMS+ to be measured objectively in a subsequent trial assessing the effectiveness of ePAMS+. Quantitative data collection will determine the feasibility of extracting data and deriving key summaries of antimicrobial prescribing; we will quantify variability in the primary outcome, number of antibiotic defined daily doses, to inform the future larger-scale trial design.
DISCUSSION CONCLUSIONS
This trial is essential to determine the feasibility of implementing the ePAMS+ intervention and measuring relevant outcomes, prior to evaluating its clinical and cost-effectiveness in a full scale hybrid cluster-randomised stepped-wedge clinical trial. Findings will be shared with study sites and with qualitative research participants and will be published in peer-reviewed journals and presented at academic conferences.
TRIAL REGISTRATION BACKGROUND
The qualitative and Fidelity Index research were approved by the Health and Research Authority and the North of Scotland Research Ethics Service (ref: 19/NS/0174). The feasibility trial and quantitative analysis (protocol v1.0, 15 December 2021) were approved by the London South East Research Ethics Committee (ref: 22/LO/0204) and registered with ISRCTN ( ISRCTN 13429325 ) on 24 March 2022.

Identifiants

pubmed: 36709308
doi: 10.1186/s40814-022-01230-w
pii: 10.1186/s40814-022-01230-w
pmc: PMC9883604
doi:

Types de publication

Journal Article

Langues

eng

Pagination

18

Subventions

Organisme : Programme Grants for Applied Research
ID : NIHR RP-PG-0617-20009

Informations de copyright

© 2022. The Author(s).

Références

Tob Induc Dis. 2021 Apr 08;19:24
pubmed: 33841063
J Med Internet Res. 2020 Jun 10;22(6):e15068
pubmed: 32519968
J Antimicrob Chemother. 2012 Jul;67 Suppl 1:i51-63
pubmed: 22855879
J R Soc Med. 2017 Aug;110(8):320-329
pubmed: 28730922
Lancet. 2005 Feb 12-18;365(9459):579-87
pubmed: 15708101
Int J Pharm Pract. 2017 Feb;25(1):5-17
pubmed: 27198585
Addiction. 2020 Feb;115(2):368-380
pubmed: 31496033
J Hosp Infect. 2019 Apr;101(4):426-427
pubmed: 30826342
J Hosp Infect. 2019 Nov;103(3):268-275
pubmed: 31394146
BMC Public Health. 2016 Jun 10;16:501
pubmed: 27287429
Implement Sci. 2016 Dec 12;11(1):163
pubmed: 27955683
BMJ. 2014 Mar 07;348:g1687
pubmed: 24609605
J Consult Clin Psychol. 2005 Oct;73(5):852-60
pubmed: 16287385
Lancet. 2016 Jan 9;387(10014):176-87
pubmed: 26603922

Auteurs

Christopher J Weir (CJ)

Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK. Christopher.Weir@ed.ac.uk.

Imad Adamestam (I)

Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK.

Rona Sharp (R)

Usher Institute, University of Edinburgh, Edinburgh, UK.

Holly Ennis (H)

Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK.

Andrew Heed (A)

Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK.

Robin Williams (R)

Institute for the Study of Science, Technology and Innovation, University of Edinburgh, Edinburgh, UK.

Kathrin Cresswell (K)

Usher Institute, University of Edinburgh, Edinburgh, UK.

Omara Dogar (O)

Usher Institute, University of Edinburgh, Edinburgh, UK.
Department of Health Sciences, University of York, York, UK.

Sarah Pontefract (S)

Institute of Clinical Sciences, University of Birmingham, Birmingham, UK.

Jamie Coleman (J)

Institute of Clinical Sciences, University of Birmingham, Birmingham, UK.

Richard Lilford (R)

University of Birmingham, Birmingham, UK.

Neil Watson (N)

Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK.
NHS Covid Vaccine North East and North Cumbria, Carlisle, UK.

Antony Chuter (A)

Usher Institute, University of Edinburgh, Edinburgh, UK.

Jillian Beggs (J)

Usher Institute, University of Edinburgh, Edinburgh, UK.

Sarah Slight (S)

School of Pharmacy, Newcastle University, Newcastle, UK.

James Mason (J)

Warwick Medical School, University of Warwick, Coventry, UK.

Lucy Yardley (L)

School of Psychological Science, University of Bristol, Bristol, UK.
School of Psychology, University of Southampton, Southampton, UK.

Aziz Sheikh (A)

Usher Institute, University of Edinburgh, Edinburgh, UK.

Classifications MeSH